Navigation Links
Cardium Reports On Third Quarter 2013 Financial Results And Recent Business Developments
Date:11/19/2013

d with the release of endogenous growth factors.  Excellagen's unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.  For more information about Excellagen, visit www.excellagen.com.

About GenerxGenerx [Ad5FGF-4] alferminogene tadenovec is a disease-modifying regenerative medicine biologic that is being developed to offer a one-time, non-surgical therapy for the treatment of cardiac microvascular insufficiency due to myocardial ischemia in patients with stable angina due to advancing coronary artery disease.  Similar to surgical and mechanical revascularization approaches, the goal of Cardium's Generx product candidate is to improve blood flow to the heart muscle, following a single, non-surgical administration using a standard balloon angioplasty catheter.  The ASPIRE Phase 3 registration study is currently being conducted at leading cardiology centers in the Russian Federation to evaluate the continued safety and therapeutic effects of Generx.  For more information about Generx and the ASPIRE clinical study, visit www.cardiumthx.com/generx.html.

About LifeAgainLifeAgain Insurance Solutions is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of "survivable risk" term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obt
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Unusual Trading Activity In Cardium Common Stock
2. Cardium Reports On Potential Use Of Excellagen To Repair Prenatally Diagnosed Birth Defects Using Mesenchymal Stem Cells
3. Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties
4. Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical Facilities
5. Cardium Completes Preferred Stock Financing
6. Cardium Announces Reverse Stock Split
7. Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
8. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
9. Cardium Announces Generx Publication In Molecular Therapy
10. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
11. Cardium Presents Year-End 2012 Financial Results And Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Ga. , Oct. 31, 2014  Digirad Corporation ... to PDI, Inc. (Nasdaq: PDII ), a ... of Digirad,s proposal to acquire the company.  ... meaningful discussions regarding a transaction and to operate in ... its cash, or take on additional debt, on acquisitions ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... DEERFIELD, Ill. and OSAKA, Japan, February 23, 2011 ... that Takeda Global Research & Development Center, Inc. ... the U.S. Food and Drug Administration (FDA) for ... chlorthalidone (CLD) for the treatment of hypertension, or ...
... Pharmaxis, a global specialty pharmaceutical company focused on therapeutic ... the commercial launch of ARIDOL® (mannitol inhalation powder) ... challenge test in more than two decades and the ... used to assess bronchial hyperresponsiveness in patients six years ...
Cached Medicine Technology:Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 2Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 3Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness 2Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness 3Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness 4Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness 5
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... DARIEN, IL – New research suggests that insomnia is ... crashes and other unintentional fatal injuries. The results underscore ... of the National Healthy Sleep Awareness Project. , Results ... in a dose-dependent manner with the number of insomnia ... were 2.8 times more likely to die from a ...
(Date:10/31/2014)... October 31, 2014 The Suspension Revolution ... workout program was developed by Dan Long, a suspension ... as a fitness professional and life coach. The author ... having toned muscles is not impossible , The Suspension ... suspension training. Suspension training promises efficiency when it comes ...
(Date:10/31/2014)... 31, 2014 Florida Air Academy, ... girls in grades 6-12, is taking the lead ... injuries and concussions, becoming the first high school ... (Immediate Post-Concussion Assessment and Cognitive Testing) computerized assessment ... Player' lawsuit grabs the headlines, and the Centers ...
Breaking Medicine News(10 mins):Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3
... byproduct even showed protection for women, study finds, , , ... byproduct that some research has linked to certain cancers, ... and may even offer slight protection for women, new ... than 120,000 men and women, Dutch researchers reported that ...
... of the American Academy of Disaster Medicine,s (AADM), Gary ... from a disaster medicine perspective on the recent swine ... why improvements are needed to the U.S. public health ... or pathogen; how disaster medicine specialists are helping other ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ... invited to listen to the conference call that will be ... at 4:30 pm Eastern Time (1:30 pm Pacific Time).A live ... DURECT,s homepage at http://www.durect.com ...
... In the wake of media reports on the outbreak ... services company, is offering advice to travelers who may already ... take.Over one million American businesspeople, expatriates, students studying abroad and ... offers five basic tips:, , ...
... Offers Significant Improvement - , , CHICAGO ... at the American Urological Association,s (AUA) Annual Conference show ... and sustained improvements of both irritative and obstructive urinary ... within three to four days of starting treatment. ...
... deaths are likely , , TUESDAY, April 28 (HealthDay News) -- ... United States continued to climb Tuesday, to 64, with all ... York City high school that had previously reported 18 cases ... are 64 confirmed cases in the United States in five ...
Cached Medicine News:Health News:Acrylamide Doesn't Raise Lung Cancer Risk 2Health News:Acrylamide Doesn't Raise Lung Cancer Risk 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:Combating Swine Flu: HTH Worldwide Offers Tips to Travelers 2Health News:Combating Swine Flu: HTH Worldwide Offers Tips to Travelers 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 2Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 4Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 5Health News: U.S. Swine Flu Cases Surpass 60 2Health News: U.S. Swine Flu Cases Surpass 60 3
... experience, the SSD-1000 is a high performance ... our advanced technologies and over 5 decades ... technology as our more expensive systems, the ... compact and mobile setting., We also employ ...
... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
The DuraSeal System includes an innovative polyethylene glycol hydrogel sealant and applicator packaged in a single-use kit which can be stored at room temperature for convenience and quick preparati...
... and Tissue Adhesive is a formulation of ... mussel). These proteins are the key components ... to anchor itself to solid substrates in ... Tissue Adhesive is used to attach cells ...
Medicine Products: